Researchers have completed patient enrollment for a clinical trial testing a new treatment for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The treatment, called intranasal foralumab, is a monoclonal antibody delivered through the nose, which may help modulate the immune system and reduce neuroinflammation. This trial is significant as it is the first Phase 2 placebo-controlled study of this type, involving 48 patients across several U.S. sites.

For people living with na-SPMS, this new treatment could mean better management of their condition, which currently has limited options. If successful, intranasal foralumab may help improve symptoms or stabilize the disease, potentially enhancing quality of life. The trial will assess the treatment’s effects over 12 weeks, with results expected later this year, followed by a six-month extension phase where all participants can receive the treatment.

The evidence is still emerging, as this is a Phase 2 trial, which means it is designed to evaluate the treatment’s effectiveness and safety in humans but is not yet conclusive. While early results from a smaller group of patients have shown some promise, the larger trial will provide more robust data to determine if intranasal foralumab can be a viable therapy for na-SPMS.

If you or someone you know is affected by na-SPMS, keep an eye on the results from this trial, as they may lead to new treatment options in the future. Always consult with a healthcare provider before considering new therapies.

Source: globenewswire.com